These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23587780

  • 1. Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
    Zelenitsky SA, Rubinstein E, Ariano RE, Zhanel GG, Canadian Antimicrobial Resistance Alliance.
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i67-72. PubMed ID: 23587780
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.
    Walkty A, Baxter M, Adam H, Karlowsky JA, Lagacé-Wiens P, Hoban DJ, Zhanel GG.
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):361-4. PubMed ID: 22694789
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.
    Zelenitsky SA, Ariano RE, Zhanel GG.
    J Antimicrob Chemother; 2011 Feb; 66(2):343-9. PubMed ID: 20926397
    [Abstract] [Full Text] [Related]

  • 4. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y.
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [Abstract] [Full Text] [Related]

  • 5. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM, Kuti JL, Nicolau DP.
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [Abstract] [Full Text] [Related]

  • 6. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
    Alişkan H, Colakoğlu S, Turunç T, Demiroğlu YZ, Erdoğan F, Akin S, Arslan H.
    Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.
    Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP.
    Clin Ther; 2009 Nov; 31(11):2678-88. PubMed ID: 20110010
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V.
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [Abstract] [Full Text] [Related]

  • 9. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN, Clark RB, Karlowsky JA, Ramirez J, Bordon JM.
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.
    Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey MR, McCracken M, Zhanel GG.
    Diagn Microbiol Infect Dis; 2017 Jan; 87(1):60-63. PubMed ID: 28336136
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR, Burgess DS.
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Kádár B, Szász M, Kristóf K, Pesti N, Krizsán G, Szentandrássy J, Rókusz L, Nagy K, Szabó D.
    Acta Microbiol Immunol Hung; 2010 Sep; 57(3):235-45. PubMed ID: 20870595
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 15. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P, Hasçelik G, Unal S.
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.
    Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ, Canadian Antimicrobial Resistance Alliance.
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i7-22. PubMed ID: 23587781
    [Abstract] [Full Text] [Related]

  • 17. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Pseudomonas aeruginosa: antimicrobial resistance in clinical isolates. Castellón 2004-2008].
    Pardo Serrano FJ, Tirado Balaguer MD, García Zúñiga ED, Granados Ortega J, Campos Aznar A, Moreno Muñoz R.
    Rev Esp Quimioter; 2010 Mar; 23(1):20-6. PubMed ID: 20232020
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.